New Uses for Common Drug May Help Patients with Inflammatory Diseases
By Lynn McCain | September 19
An article recently published by the Nuñez lab provides an exciting discovery for individuals with Alzheimer’s disease, diabetes, and certain other autoimmune diseases caused by aberrant NLRP3. The research, led by Dr. Jie Xu with Drs. Joseph Pickard and Gabriel Nuñez, discovered that a common, safe, FDA-approved drug used to treat alcoholism and cocaine addictions, disulfiram, inhibits the production of NLRP3 inflammasomes. When NLRP3 is activated, it can cause inflammation leading to multiple health issues.
The discovery that disulfiram, which has a long history of use, inhibits the activation of the processes leading these diseases is fantastic news for patients who need effective, safe treatments.
Per Nuñez, “There are several diseases for which disulfiram potentially could be effective, but additional clinical trials are needed.”
For more information on this article, see the news story published by Michigan Medicine’s Health Lab.
Citation:
Jie Xu, Joseph M. Pickard, Gabriel Nuñez. FDA-approved disulfiram inhibits the NLRP3 inflammasome by regulating NLRP3 palmitoylation. (2024) Cell Reports. DOI: 10.1016/j.celrep.2024.114609
ON THE COVER
ON THE COVER
ON THE COVER
ON THE COVER
ON THE COVER
ON THE COVER
ON THE COVER
ON THE COVER
ON THE COVER
ON THE COVER
